uric acid has been researched along with Gingival Hyperplasia in 1 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Gingival Hyperplasia: Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells. (From Jablonski's Dictionary of Dentistry, 1992, p400)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study we aimed at evaluating the modifications in the pharmacokinetic profile of cyclosporin A (CyA) after conversion from standard formulation (CyA-ST) to a new formulation (CyA-NF, Sandimmun Neoral) in patients with rheumatoid arthritis (RA)." | 2.69 | Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ( Battafarano, N; Fantini, F; Leoni, L; Marchesoni, A; Padula, A; Pasero, G; Ruiu, G; Taglione, E; Zeni, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marchesoni, A | 1 |
| Fantini, F | 1 |
| Battafarano, N | 1 |
| Zeni, S | 1 |
| Ruiu, G | 1 |
| Padula, A | 1 |
| Taglione, E | 1 |
| Pasero, G | 1 |
| Leoni, L | 1 |
1 trial available for uric acid and Gingival Hyperplasia
| Article | Year |
|---|---|
Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Biological Availability; Blood Pressure; Chemistry, Pharma | 1998 |